HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
PDF version here Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer. Robert Coleman PhD, MBA, […]
HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board
PDF version here • Prof Langer is a world-renowned scientist and entrepreneur who was a driving force behind Moderna’s mRNA nanoparticle Covid vaccine • Prof Langer has joined HERVOLUTION to develop HERVs that are a novel untapped target in oncology and senescence related diseases • Prof Langer’s scientific knowledge and entrepreneurial expertise will help expedite HERVOLUTION’s lead candidate […]
Hervolution announces EUR 6M Seed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy
Download PDF version here • Danish start-up developing immunotherapies designed to fight the tumors from within • Financing supports GMP and tox studies and will advance Hervolution’s first-in-class cancer immunotherapy into First-in-Human clinical trials • Strengthens team with appointment of industry heavyweights Dr. Sven Rohman as Chairman and Dr. Hamina Patel as CMO Copenhagen, Denmark, 24 May 2023: Hervolution, an early-stage biotechnologycompany developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), today announces that it has raised EUR 6M of Seed funding from private investors with the participation of the European Innovation Council (EIC) Fund. The financing will […]
Hervolution has been awarded an EU grant to further explore the role of IPT001 in oncological immunotherapy approaches against hard to treat cancers
This initiative aims to advance our understanding of the potential applications of IPT001 in enhancing oncological immunotherapy, ultimately contributing to the development of more effective treatment strategies for cancer patients. “Significant progress has been made as Hervolution secures a substantial EU fund to expand its research efforts into utilizing IPT001 within the field of oncological […]
